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Abstract The objective of the present study was to
evaluate the effect of the switch of aromatase inhibitors
(AIs) on musculoskeletal symptoms in postmenopausal
women with hormone-receptor-positive breast cancer. This
was a 6-month, prospective, non-randomized, multicenter
study. Patients who had discontinued anastrozole due to
musculoskeletal symptoms were eligible to participate in
this study, and received letrozole, which was initiated 1
month after anastrozole discontinuation. Musculoskeletal
symptoms were systematically assessed for severity, loca-
tion of the symptoms, presence of swelling and of morning
stiffness by the oncologist patients when patients stopped
taking their anastrozole, 1 month after the discontinuation
of anastrozole, and 1, 3, and 6 months after initiating the
letrozole therapy. The primary endpoint was the percentage
of patients who discontinued letrozole due to the severe
musculoskeletal symptoms. After switching from anas-
trozole therapy, and at the end of the 6-month letrozole
treatment, 128 (71.5%) out of 179 patients (61.3 ±
8.4 years) continued with letrozole. Fifty-one patients
(28.5%) discontinued treatment due to severe joint pain. At
the end of the 6-month, 116 patients (73.9%) had
arthralgia, 33 (21.0%) myalgia, 25 (15.9%) arthritis, 22
(14.0%) tendinitis, and 20 (12.7%) polyalgic syndrome.
Bivariate analysis of the factors associated with letrozole
discontinuation showed that the duration of a prior anas-
trozole treatment was a significant predictor (P = 0.04).
This study shows that in patients intolerant to one AI,
switching to another agent allows a higher proportion of
patients to continue the therapy and maximize hormonal
adjuvant therapy and disease outcome benefits.
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Introduction
Aromatase inhibitors (AIs) have been rapidly replacing
tamoxifen as the standard of care for adjuvant therapy for
postmenopausal women with hormone-receptor-positive
(HR?) breast cancer [1–6]. Several clinical studies have
shown that the third generation AIs (e.g., anastrozole,
letrozole, and exemestane) are superior to tamoxifen in
reducing the risk of disease recurrence in an adjuvant set-
ting irrespective of treatment strategy either at the start of
adjuvant treatment or after 2–3 years of tamoxifen treat-
ment [2–4].
The efficacy of AIs relies on inhibiting the aromatization
of androgens which in turn causes estrogen depletion [7, 8],
in contrast with tamoxifen, a selective estrogen receptor
modulator, which blocks estrogen activity by binding to the
receptors. An increase in the incidence of musculoskeletal
symptoms such as arthralgia, arthritis, joint pain or myal-
gia, have been observed during AI therapy when compared
to tamoxifen [9, 10], as expected with decreased estrogen
concentration. Musculoskeletal symptoms have been
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reported with each of the three AIs and are considered as an
adverse event related to this class of drug. Of 200 patients
who participated in one adjuvant AI study, 88 (44%)
reported onset or worsening of joint pain, with nearly 5%
discontinuing their treatment [10]. More recently, studies
have revealed an increase in tenosynovial changes in
women taking AIs compared to those on tamoxifen [11,
12]. The mechanism of AI-associated musculoskeletal
symptoms is unclear, and it is has been reported that
increased pain sensitivity on nociceptive fibers may be due
to estrogen deprivation at the cartilage and periarticular
tissues [8, 13]. Musculoskeletal symptoms can be severe,
limiting normal daily activity and potentially lead to the
discontinuation of an AI treatment. Partridge et al. [14]
analyzed data from three large commercial health programs
longitudinal databases and found that the adherence to
adjuvant anastrozole therapy decreased from 69–78% in
the first year and to 50–68% in the third year; however, in
this study, reasons for non-persistence, including severe
side effects or adverse events, were not evaluated.
Given the significant benefits of AIs on disease outcome,
a majority of postmenopausal women with HR? breast
cancer will attempt to tolerate the musculoskeletal symp-
toms. When pain is severe and unresponsive to available
treatment (analgesics, non-steroidal anti-inflammatory
drugs), patients may be switched from one AI to another or
possibly to another therapy such as tamoxifen. Renshaw
et al. [15] reported that nearly 50% of patients experienced
joint pain relief when switched from either anastrozole to
letrozole or visa versa.
To date, no clinical study has documented the course of
musculoskeletal symptoms in postmenopausal women with
HR? breast cancer after switching from one AI to another
due to severity of the musculoskeletal symptoms. The
objective of this study was design to evaluate the effect of
the switch of AIs on musculoskeletal symptoms in post-
menopausal women with HR? breast cancer, and to
identify the factors associated with subsequent discontin-
uations from AI therapy. This trial also evaluates the
prevalence and severity of the musculoskeletal symptoms.
Patients and methods
Study design
This was a prospective, non-randomized, open-label, and
multicenter trial. This study was conducted between 2005
and 2007 in 37 clinical centers across France. The obser-
vation period lasted for 7 months from enrollment and
included a 1-month washout followed by 6 months of
letrozole treatment (Fig. 1). At visit 1 (baseline visit)
patients stopped taking their anastrozole due to lasting
presence of musculoskeletal symptoms. Visit 2 was
scheduled 1 month after the discontinuation of anastrozole,
and visits 3, 4, and 5 were scheduled at months 1, 3, and 6,
respectively, after initiating the letrozole therapy.
Patients and eligibility criteria
Eligible patients were postmenopausal women with HR?
breast cancer treated with adjuvant anastrozole who were
experiencing lasting and severe musculoskeletal symptoms
to the point of stopping their treatment. Patients who wanted
to stop anastrozole were proposed to be switched to letrozole
after a 1-month washout and were included in a 6-month
open study. Patients were required to have adequate
hematopoietic function (PNN C 1200 mm-3, platelets C
100000 mm-3, Hb C 10 g dl-1) and satisfactory liver
function (bilirubin B 30 lmol l-1, transaminases \ 3 N).
They were excluded from the study if they (i) were hyper-
sensitive to any component of letrozole, (ii) had metastatic
disease, (iii) had bone fracture-related pain, (iv) were on a
hormonal therapy (e.g., tamoxifen, GnRH agonists) other
than anastrozole, and/or (v) if they were incapacitated or had
poor cognitive function preventing them to comply with the
required assessments.
The study was approved by a central institutional review
board, a local review boards, and the local ethic committee
for medical research. This study was conducted in accor-
dance with the Declaration of Helsinki (revised in 1983).
Written and oral informed consents were obtained from all
patients.
Treatment
One month after stopping anastrozole, letrozole 2.5 mg per
day was administered (orally) for 6 months or until the
treatment was discontinued due to intolerance or disease
progression. After the 6-month treatment, the decision of
continuation or not of letrozole was left to the physician of
the patient.
*Patients discontinued anastrozole at Visit 1. 
Letrozole (2.5 mg day–1) was administered orally for 6 months 
Month 1 Month 3 Month 6 









Fig. 1 Study design representing the visit schedule for aromatase
inhibitor (AI) switching. * Patients discontinued anastrozole at visit 1.
Letrozole (2.5 mg day-1) was administered orally for 6 months
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Endpoints
The primary endpoint of the study was the percentage of
postmenopausal women who discontinued the letrozole
treatment due to severe musculoskeletal symptoms after
switching from anastrozole. The secondary endpoints of
the study included the following: (i) characterization of the
musculoskeletal symptoms (e.g., location, severity, and
impact of pain on daily life), (ii) persistence to letrozole
treatment using patient report, and (iii) identification of the
predictors of letrozole discontinuation.
Study assessments
Demographic data, a clinical assessment, and the Eastern
Cooperative Oncology Group (ECOG) score were col-
lected when patients stopped taking anastrozole (visit 1—
V1, baseline), 1 month after the discontinuation of anas-
trozole (visit 2—V2), 1 month (visit 3—V3), 3 months
(visit 4—V4), and 6 months (visit 5—V5) after the
beginning of letrozole. The ECOG Performance Status
Rating measures how cancer affects the daily living
abilities of the patient, the scale ranges from 0 (fully
active, no restrictions) to 5 (dead). At each visit, the
presence and level of musculoskeletal symptoms system-
atically assessed for severity, location of the symptoms,
presence of swelling and of morning stiffness was evalu-
ated by the oncologist. Arthralgia excluded swelling and
synovitis and arthritis indicates joint inflammation leading
to pain and swelling. Muscle and tendon pain were also
assessed; chronic widespread pain, non-restorative sleep,
adverse events, concomitant treatments including analge-
sics were also collected. Polyalgic syndrome was defined
by multiple tender points, general asthenia and leading to
altered sleep.
At each visit, a French version of the brief pain inven-
tory (BPI) was used to assess the severity of pain and the
impact of pain on daily function. The BPI short question-
naire asks questions about pain relief, quality of the pain,
and the patient’s perception in relation to the possible cause
of the pain. The BPI is based on a scale from 0 to 10, a
score of 7 or higher on the scale represents a more severe
level of (versus mild or moderate) pain [16, 17]. Quality of
life (QoL) was assessed with French versions of the Health
Assessment Questionnaire (HAQ) (a scale ranging from 0
to 3; higher values indicating more disability), and the SF-
12. The SF-12 is a subset of 12 questions from the SF-36
Health Survey which assesses subscales for a physical and
a mental component in relation with quality of life [17–19].
The scores could range from 0 to 100, where higher scores
indicated better QoL. Routine hematology and biochem-
istry parameters (erythrocyte sedimentation rate (ESR),
C-reactive protein, muscle enzymes, vitamin D, calcium,
and phosphorus) were also assessed at baseline and
6 months after initiation of letrozole.
Data analysis and statistical methods
It was hypothesized that there would be a 50% discontin-
uation rate due to musculoskeletal pain with letrozole.
Therefore, it was calculated that the study would require
171 evaluable patients out of a possible 200 patients to
obtain a 95% CI of 50 ± 7.5% (NQuery Advisor v 4.0).
All the analysis were performed on the intent-to-treat (ITT)
population which included all patients who received one
dose of letrozole. Demographics and clinical characteristics
were analyzed using descriptive analyses (mean ± SD,
median and range) for continuous variables, and the per-
centage as well as frequency for nominal variables. Con-
tinuous and ordinal secondary parameters were described
at each time point and in terms of change from baseline.
Wilcoxon’s signed rank test was used for comparisons to
baseline. Categorical parameters were described using
frequency tables at each time point. Finally, a search for
possible predictors of letrozole discontinuation was
explored by a chi-square test and the data was analyzed
using SAS v8.02.
Results
This study enrolled 179 patients over 2 years. Patient
demographic data and baseline characteristics are shown in
Table 1.
Characteristics of patients who discontinued
anastrozole (baseline visit)
All patients who were enrolled in this study discontinued
anastrozole due to severe and lasting musculoskeletal
symptoms. The mean duration of anastrozole treatment
before discontinuation was 14.3 months (Table 1). At the
baseline visit, 156 patients (87.2%) reported symptoms of
arthralgia, 71 (39.7%) myalgia, 49 (27.4%) polyalgic
syndrome, 36 (20.1%) tendinitis, and 31 (17.3%) arthritis
(Fig. 2a). The most commonly affected joints were those
located in the hands, knees, and spine (Fig. 2b). The joint
symptoms were associated with morning stiffness in 55
(34.1%) of patients. There were 130 (72.6%) of patients
who reported at least four or more affected joints (Fig. 2c).
27.9% of patients reported joint symptoms at the hands.
The pain intensity assessed as a mean BPI score was
4.9 ± 1.6 (Table 1). There were 70% of patients who
reported mean BPI scores between 4 and 7, with 40.8% of
them taking over minor analgesics and 22.9% on moderate
Breast Cancer Res Treat (2010) 120:127–134 129
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opioids. At the baseline visit, biochemical markers of
inflammation (ESR and C protein reactive) were assessed
and within the normal range.
Characteristics of patients at the end of letrozole
treatment
At the end of the 6-month study, 128 (71.5%) of patients
were still taking letrozole (95% CI = 64.9–78.1) and 51
(28.5%) had discontinued their treatment (95% CI = 21.9–
35.1) due to musculoskeletal symptoms.
Among the patients who stopped letrozole for joint
symptoms, 17 (9.5%) patients stopped before the end of the
first month of treatment. In these patients, the most com-
monly reason for treatment discontinuation was due to joint
pain of spine (64.7%), hands (52.9%), knees (52.9%), and
ankles (52.9%).
At the end of the 6-month treatment with letrozole, 116
(73.9%) patients had arthralgia, 33 (21.0%) myalgia, 25
(15.9%) arthritis, 22 (14.0%) tendinitis, and 20 (12.7%)
polyalgic syndrome. There were 24 (15.3%) patients who
did not report any joint pain. Joint pain was associated with
morning stiffness in 38 (24.2%) women. Overall, fewer
women reported arthralgia, arthritis, tendinitis, and pol-
yalgic syndrome after the switch (Fig. 2a). The effect of
switching to letrozole was observed across all commonly
affected joints (Fig. 2b). The most common joints affected
were hands (45.9%), knee (41.4%), and spine (40.8%)
(Fig. 2b). Most of women, 59 (37.6%), had at least four
joints from which they reported some level of discomfort
(Fig. 2c).
After the 1-month or washout period, the mean BPI,
HAQ, and SF-12 for the physical and mental scores
were 3.7 ± 2.7, 1.7 ± 0.6, 41.5 ± 8.9, 44.1 ± 11.2,
respectively (Tables 2, 3, and 4). After completing
6 months of letrozole treatment, the mean BPI was 3.8 ±
2.4 (median = 3.5; range = 0–9.3) decreasing 19% from
baseline when the patient had previously been on anas-
trozole (Table 2). Additionally, a significant improvement
in QoL was also observed after switching to letrozole
(Tables 3 and 4). This improvement is reflected by the
mean change in the scores after 6 months of letrozole
from the baseline visit: there was a significant decrease in
BPI (-1.2 ± 2.3, P \ 0.001) and HAQ (-0.3 ± 0.5,
P \ 0.001) with a significant improvement in the SF-12
physical and mental scores of ?5.2 ± 9.5, P \ 0.001,
?2.7 ± 11.3 (P = 0.01, respectively) (Tables 2, 3, and
4). There was also a decrease in the usage of analgesics
observed in 49 (31.2%) patients who were taking minor
analgesics and 35 (22.7%) patients on moderate opioids.
There were no significant changes in biochemical markers
of inflammation during the 6-month study (data not
shown here).
Bivariate analyses assessing the possible factors asso-
ciated with the discontinuation with letrozole found only
one statistically significant predictor which was the prior
duration of anastrozole therapy. A shorter duration of
anastrozole treatment was associated with a higher risk of
letrozole discontinuation (P = 0.04). There was no sig-
nificant association between the discontinuation of letroz-
ole treatment with respect to age, duration of menopause,
body mass index (BMI), socio-demographic status, and a
history of osteoarthritis.
Discussion
Despite the established benefits of AI therapy on improving
disease-free survival, AIs result in increased musculoskel-
etal symptoms compared to tamoxifen which may limit
treatment persistence and long-term observance [9–13].
These effects must be anticipated, managed by non-
Table 1 Patient demographics and baseline characteristics (visit 1)
Characteristics of women who stopped anastrozole N = 179
Age (years) 61.3 ± 8.4
Weight (kg) 68.8 ± 14.1
BMI (kg m-2) 26.1 ± 4.7
ECOG score (0–5) 0.7 ± 0.6
Previous osteoarthritis (%) 72 (40.2)
Duration of menopause (years) 10.4 ± 8.9
Mood disorder treated, n (%) 34 (19)
Duration of prior treatment of anastrozole (months) 14.3 ± 10.5
Previous intake of anastrozole, n (%)
\6 months 49 (27.4)
C6 and \12 months 43 (24.0)
C12 and \24 months 54 (30.2)
[24 months 33 (18.4)
BPI short-form score (0–7) 4.9 ± 1.6
SF-12 physical score (0–100) 37.1 ± 8.5
SF-12 mental score (0–100) 40.8 ± 11.0
HAQ (0–3) 2.0 ± 0.5
ESR (mm/first hour) (B30 mm) 15.6 ± 13
C-reactive protein, mg m-1 (normal B5 mg m-1) 5.0 ± 12.6
Calcium, mmol l-1 (2.2–2.6) 2.39 ± 0.1
Phosphorus, mmol l-1 (0.9–1.3) 1.21 ± 0.20
Creatinine phosphokinase, ukat l-1(normal \3.3) 1.55 ± 1.0
Serum 25-OH-vitamin D, nmol l-1
(normal C 75 nmol/l)
50 ± 31.7
All values are shown mean ± SD
BPI brief pain inventory, BMI body mass index, ECOG Eastern
Cooperative Oncology Group, ESR erythrocyte sedimentation rate,
HAQ health assessment questionnaire, SF-12 12-item short-form
130 Breast Cancer Res Treat (2010) 120:127–134
123
pharmacological and pharmacological interventions. One
such approach could be to switch from one AI to another as
shown in this study. Our data suggests that switching from
one AI to another allowed 70% of patients to continue their
treatment for over 6 months and is a mean to maximize the
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a proportion of patients with
symptoms, b proportion of
patients with the most
commonly affected joints as
assessed by the investigator,
c proportion of patients with the
number of affected joints
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Few studies have assessed the symptomatic effects of
switching AIs on musculoskeletal symptoms in postmen-
opausal women with HR? breast cancer. In a study of 170
patients that compared anastrozole, letrozole, and a
switching regimen, 131 (77%) reported joint pain with AI
therapy and 10 patients reported joint stiffness [15]. There
was no difference in the incidence of joint stiffness or pain
between patients receiving anastrozole or letrozole. Of the
patients who reported joint symptoms with either anas-
trozole or letrozole, and switched at 12 weeks to another
AI, about half had persistent symptoms and about half did
not [15]. In a single-blind crossover trial which aimed to
assess whether tolerance for either letrozole or anastrozole
can differ in terms of early quality of life (QoL), 72 breast
cancer patients who had experienced tamoxifen failure
were randomized to letrozole or anastrozole (either
letrozole or anastrozole for 4 weeks, 1 week off, then
crossover for 4 weeks) [20]. 68% of patients preferred to
continue letrozole compared to 32% of those who were
receiving anastrozole (P \ 0.01) [20].
Hormonal changes in postmenopausal women affect
their musculoskeletal health. As a consequence of estrogen
deprivation, the occurrence of joint pain increases with age
and reaches a peak in women aged 50–59 years [8, 21, 22].
Postmenopausal status is a strong independent predictor
associated with increased musculoskeletal symptoms in
women [8]. Therefore, AI-related effects may have addi-
tive consequences in these patients.
In a cross-sectional survey of 200 patients who were
receiving an adjuvant AI therapy, nearly half of them
reported arthralgia of the hands, knees, and spine [10]. In
the present study, we observed that patients who switched
to letrozole after experiencing severe musculoskeletal pain
with anastrozole reported similar musculoskeletal symp-
toms (type and location) (Fig. 2a, b). We observed a good
persistence over 6 months, although there was only a slight
decrease of 6–18% in the number of patients experiencing
arthralgia, myalgia, or tendinitis after switching from
anastrozole to letrozole (Fig. 2a). There was a substantial
decrease in the number of patients (*35%) with four or
more afflicted joints (Fig. 2b, c), and a 19% decrease in the
severity of pain (mean BPI) was noticed after switching.
The incidence of the joint pain symptoms reported in
this study is higher (70%) compared to that reported in
another clinical setting study (50%) (10) and the adjuvant
trials (20–30%) [2–4]. This may well be attributed to the
inclusion criteria of our study that limited enrollment to
postmenopausal women with HR? breast cancer on
Table 2 BPI (brief pain







Visit 1 baseline 176 4.9 ± 1.6
Visit 2 175 3.7 ± 2.2 -1.1 ± 1.9 \0.001
Visit 3 171 3.5 ± 2.1 -1.4 ± 1.9 \0.001
Visit 5 or premature stop 149 3.8 ± 2.4 -1.2 ± 2.3 \0.001
Table 3 HAQ (health
assessment questionnaire) score






Visit 1 baseline 176 2.0 ± 0.5
Visit 2 176 1.7 ± 0.6 -0.3 ± 0.5 \0.001
Visit 3 175 1.7 ± 0.5 -0.3 ± 0.5 \0.001
Visit 5 or premature stop 150 1.7 ± 0.6 -0.3 ± 0.5 \0.001
Table 4 SF-12 (physical and mental) scores changes over the study










Visit 1 baseline 168 37.1 ± 8.5 40.8 ± 11.0
Visit 2 165 41.5 ± 8.9 4.6 ± 8.4 \0.001 44.1 ± 11.2 3.8 ± 9.1 \0.001
Visit 3 157 42.1 ± 9.2 5.0 ± 9.4 \0.001 44.4 ± 11.0 3.8 ± 11.2 \0.001
Visit 5 or premature stop 146 41.7 ± 9.5 5.2 ± 9.5 \0.001 43.1 ± 9.9 2.7 ± 11.3 0.01
132 Breast Cancer Res Treat (2010) 120:127–134
123
anastrozole who were experiencing more severe joint pain,
and decide to stop treatment because of these symptoms.
In this study, the single predictor for second AI dis-
continuation was the duration of the previous one sug-
gesting that some patients may be intolerant to any of AI.
We evaluated other potential predictor factors such as age,
BMI, years since menopause, previous osteoarthritis, but
these variables were not correlated with the presence or
severity of musculoskeletal symptoms in our patient’s
population. Previous studies have identified factors which
may influence the onset and the severity of AI-related
arthralgia. Crew et al. [10] found more than a fourfold
increase in the risk of AI-related arthralgia in patients who
received prior taxane chemotherapy. A retrospective
exploratory analysis of the ATAC trial showed that the
major risk factors for developing joint symptoms are pre-
vious use of hormonal replacement treatment, hormone-
receptor positivity, previous chemotherapy, obesity and
treatment with anastrozole [23]. All of these factors are
potentially linked with a great decrease in estrogen con-
centrations. Although, studies are conflicting concerning
the influence of body weight, in fact, Crew et al. [10] found
that patients who were overweight (BMI, 26–30 kg/m2)
were less likely to have AI-related joint pain compared
with those who had a normal BMI (25 kg/m2) or were
obese (BMI [ 30 kg/m2). Increased adiposity and
increased sex hormone levels may explain the lower
prevalence of AI-related joint pain in overweight women
compared with women with a normal BMI [24]. The pro-
tective effect was lost among obese women, may be
because of an increased risk of osteoarthritis obesity.
Actually comparisons of results of different studies must
take into account the baseline characteristics of the
patients: we included only patients who reported pain as a
criterion of entry in our trial, in contrast with Sestak et al.
[22] who studied patients without any pre-existing joint
symptoms. Musculoskeletal pain is an adverse event often
reported with this class of agent, AIs can trigger symptoms
which can be completely resolved after treatment discon-
tinuation [23]. However, in our study, we have noticed that
the 1-month washout of AI was associated with a slight
decrease in musculoskeletal pain, but the symptoms did not
resolve completely. Other studies have suggested that
switching from one AI to another may alleviate symptoms
in some women [15].
Our study has several limitations. It is an open study, and
the assessed endpoints are qualitative in nature leaving
some room for patient’s personal subjectivity. Due to the
short duration (6 months) of follow-up, we could not
exclude the occurrence of additional musculoskeletal
symptoms after the 6-month treatment period with letroz-
ole. In a single center study of 77 postmenopausal women,
Donnellan et al. [9] showed that the range of the median
duration of initiation of anastrozole intake to the onset of
symptoms can be large from 8 weeks to 16 months. We
cannot exclude that the decrease in symptoms is related to
time rather to the switch. Patients may attempt to tolerate
the second AI after considering that these symptoms are
related to this class of drugs, and that stopping such therapy
may be a loss of chance. We evaluated persistence to
letrozole using the patient report and we can not check that
they really took the treatment. Finally, this observational
study is not a comparative one, and these results cannot lead
to comparison of the tolerance of the 2 AIs.
Aromatase inhibitors use results in increased musculo-
skeletal symptoms which can be managed by non-phar-
macological and pharmacological interventions. This study
suggests that switching from one non-steroidal AI to
another one can result in prolong treatment with the adju-
vant hormonal therapy in postmenopausal women with
HR? breast cancer troubled by musculoskeletal symptoms.
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